PMC:7029759 / 36387-36597 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"952","span":{"begin":80,"end":84},"obj":"Gene"},{"id":"956","span":{"begin":27,"end":36},"obj":"Species"},{"id":"957","span":{"begin":184,"end":206},"obj":"Species"},{"id":"960","span":{"begin":172,"end":176},"obj":"Disease"}],"attributes":[{"id":"A952","pred":"tao:has_database_id","subj":"952","obj":"Gene:59272"},{"id":"A956","pred":"tao:has_database_id","subj":"956","obj":"Tax:2697049"},{"id":"A957","pred":"tao:has_database_id","subj":"957","obj":"Tax:277944"},{"id":"A960","pred":"tao:has_database_id","subj":"960","obj":"MESH:D045169"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T668","span":{"begin":27,"end":36},"obj":"SP_7"},{"id":"T667","span":{"begin":80,"end":84},"obj":"G_3;PG_10;PR:000003622"},{"id":"T666","span":{"begin":172,"end":176},"obj":"SP_10"},{"id":"T665","span":{"begin":184,"end":189},"obj":"SP_6;NCBITaxon:9606"},{"id":"T664","span":{"begin":190,"end":201},"obj":"NCBITaxon:11118"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}

{"project":"LitCovid_AGAC","denotations":[{"id":"p4619s14","span":{"begin":72,"end":79},"obj":"NegReg"},{"id":"p4619s15","span":{"begin":80,"end":84},"obj":"Protein"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T124","span":{"begin":172,"end":176},"obj":"Disease"}],"attributes":[{"id":"A124","pred":"mondo_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T375","span":{"begin":184,"end":189},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}

{"project":"LitCovid-sentences","denotations":[{"id":"T226","span":{"begin":0,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65."}